Heng Hong Technology (HCPC.US), a Chinese medicine product distributor headquartered in China, has increased the proposed size of its upcoming initial public offering as of Monday. The company, based in Chengmai County, China, now plans to offer 5 million shares priced between $6 and $7 each, aiming to raise $33 million. This marks a significant shift from its earlier filing, which sought to sell 2 million shares at $4 to $6 per share.

At the midpoint of the revised price range, the funds raised would be 225% higher than previously anticipated, giving the company a market capitalization of approximately $163 million. According to the prospectus, Heng Hong Technology primarily operates through Heng Cheng Health in China, generating revenue from the distribution of traditional Chinese medicine and chemical medical products, alongside promotional and marketing services. Its key product offerings include medications for coughs and colds, such as Ganmao Qingre Granules, Fenghan Ganmao Granules, and Yinqiao Jiedu Granules, as well as tonic medicines like Yangxue Anshen Jianpi Granules, Shengmai Granules for nourishing yin and qi, Shouwu Bushen Granules for kidney health, and Zhuangyao Jianzhen Wan for lumbar and kidney support.

The company's distribution network spans 22 provinces and autonomous regions across China. In 2025, 93.6% of its product purchases were sourced from a single supplier, where the company's chairman also serves as the general manager. Founded in 2008, Heng Hong Technology plans to list on the Nasdaq under the ticker HCPC. Kingswood Capital Markets is acting as the sole bookrunner for the transaction.